BR112018006572A2 - terapia de combinação racional para o tratamento de câncer - Google Patents
terapia de combinação racional para o tratamento de câncerInfo
- Publication number
- BR112018006572A2 BR112018006572A2 BR112018006572A BR112018006572A BR112018006572A2 BR 112018006572 A2 BR112018006572 A2 BR 112018006572A2 BR 112018006572 A BR112018006572 A BR 112018006572A BR 112018006572 A BR112018006572 A BR 112018006572A BR 112018006572 A2 BR112018006572 A2 BR 112018006572A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination therapy
- cancer treatment
- agents
- rational combination
- chaperone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
a presente invenção refere-se a métodos para usar inibidores de proteínas chaperonas, tais como inibidores de hsp90, em combinação com agentes que aumentam estresse proteotóxico em células tumorais ou agentes que induzem um recabeamento bioquímico da chaperona. os agentes proteotóxicos são administrados antes da administração das proteínas chaperonas para obter atividade sinergética.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562237470P | 2015-10-05 | 2015-10-05 | |
PCT/US2016/055594 WO2017062520A1 (en) | 2015-10-05 | 2016-10-05 | Rational combination therapy for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018006572A2 true BR112018006572A2 (pt) | 2018-10-09 |
Family
ID=57145064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018006572A BR112018006572A2 (pt) | 2015-10-05 | 2016-10-05 | terapia de combinação racional para o tratamento de câncer |
Country Status (14)
Country | Link |
---|---|
US (1) | US20180280397A1 (pt) |
EP (1) | EP3359196B1 (pt) |
JP (1) | JP7132848B2 (pt) |
KR (1) | KR20180058824A (pt) |
CN (1) | CN108472376A (pt) |
AU (1) | AU2016336351A1 (pt) |
BR (1) | BR112018006572A2 (pt) |
CA (1) | CA3000851A1 (pt) |
EA (1) | EA201890623A1 (pt) |
IL (1) | IL258494A (pt) |
MA (1) | MA47474A (pt) |
MX (1) | MX2018004112A (pt) |
TW (1) | TW201722422A (pt) |
WO (1) | WO2017062520A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2016128528A (ru) | 2013-12-23 | 2018-01-30 | Мемориал Слоун-Кеттеринг Кэнсэ Сентр | Способы и реактивы для введения радиоактивной метки |
CN110090303B (zh) * | 2019-05-07 | 2022-09-16 | 浙江大学 | 阿片受体激动剂在制造用于治疗恶性肿瘤的药物中的用途 |
CN112641949A (zh) * | 2021-01-11 | 2021-04-13 | 深圳市人民医院(深圳市呼吸疾病研究所) | 一种含有pi3k抑制剂的药物组合物及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002036171A1 (en) | 2000-11-02 | 2002-05-10 | Sloan Kettering Institute For Cancer Research | Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
AU2007269144B2 (en) | 2006-06-30 | 2013-05-16 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibition of HSP90 |
MX353747B (es) | 2009-08-17 | 2018-01-26 | Memorial Sloan Kettering Cancer Center Star | Compuesto de union a proteina de choque termico, composiciones, y metodos para producir y usar los mismos. |
ES2733131T3 (es) | 2009-10-07 | 2019-11-27 | Sloan Kettering Inst Cancer Res | Derivados de purina útiles como inhibidores de hsp90 |
EA024647B1 (ru) | 2011-04-05 | 2016-10-31 | Слоун-Кеттеринг Инститьют Фо Кэнсэ Рисерч | ИНГИБИТОРЫ Hsp90 |
CN103582642B (zh) | 2011-04-05 | 2021-05-11 | 索隆-基特林癌症研究协会 | Hsp90抑制剂 |
JP6054389B2 (ja) | 2011-07-08 | 2016-12-27 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 標識されたhsp90阻害剤の使用 |
AU2014306417C1 (en) | 2013-08-16 | 2019-07-25 | Memorial Sloan-Kettering Cancer Center | Selective Grp94 inhibitors and uses thereof |
WO2015175707A1 (en) | 2014-05-13 | 2015-11-19 | Memorial Sloan Kettering Cancer Center | Hsp70 modulators and methods for making and using the same |
-
2016
- 2016-10-05 KR KR1020187012285A patent/KR20180058824A/ko unknown
- 2016-10-05 CN CN201680069308.9A patent/CN108472376A/zh active Pending
- 2016-10-05 MA MA047474A patent/MA47474A/fr unknown
- 2016-10-05 MX MX2018004112A patent/MX2018004112A/es unknown
- 2016-10-05 JP JP2018536719A patent/JP7132848B2/ja active Active
- 2016-10-05 EP EP16782374.9A patent/EP3359196B1/en active Active
- 2016-10-05 WO PCT/US2016/055594 patent/WO2017062520A1/en active Application Filing
- 2016-10-05 AU AU2016336351A patent/AU2016336351A1/en not_active Abandoned
- 2016-10-05 BR BR112018006572A patent/BR112018006572A2/pt not_active Application Discontinuation
- 2016-10-05 US US15/765,980 patent/US20180280397A1/en not_active Abandoned
- 2016-10-05 CA CA3000851A patent/CA3000851A1/en not_active Abandoned
- 2016-10-05 TW TW105132272A patent/TW201722422A/zh unknown
- 2016-10-05 EA EA201890623A patent/EA201890623A1/ru unknown
-
2018
- 2018-04-04 IL IL258494A patent/IL258494A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20180058824A (ko) | 2018-06-01 |
EA201890623A1 (ru) | 2018-09-28 |
JP7132848B2 (ja) | 2022-09-07 |
MA47474A (fr) | 2019-12-25 |
TW201722422A (zh) | 2017-07-01 |
AU2016336351A1 (en) | 2018-05-10 |
WO2017062520A1 (en) | 2017-04-13 |
EP3359196A1 (en) | 2018-08-15 |
CA3000851A1 (en) | 2017-04-13 |
MX2018004112A (es) | 2018-06-20 |
US20180280397A1 (en) | 2018-10-04 |
EP3359196B1 (en) | 2022-03-16 |
CN108472376A (zh) | 2018-08-31 |
JP2018537519A (ja) | 2018-12-20 |
IL258494A (en) | 2018-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017007765A2 (pt) | composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo | |
BR112016004095A2 (pt) | administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores | |
BR112017012377A2 (pt) | conjugados anticorpo-fármaco com inibidores de bcl-xl permeáveis à célula | |
GT201700246A (es) | Métodos y kits para tratar la depresión | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
BR112014031088A8 (pt) | métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal | |
BR112015021115A2 (pt) | agentes para induzir apoptose para o tratamento de câncer e doenças imunes e autoimunes | |
BR112017018954A2 (pt) | uso de forma mutante de proteína ras e método para tratar câncer | |
NI201500002A (es) | Agentes de unión de rspo3 y usos de los mismos. | |
BR112016012713A2 (pt) | Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento | |
BR112015025711A2 (pt) | terapia de combinação com ibrutinibe | |
BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
BR112015023203A2 (pt) | métodos para tratamento de câncer, para aumentar a eficiência de um tratamento de câncer, para retardar e/ou prevenir o desenvolvimento de câncer, para tratar um indivíduo com câncer, para aumentar a sensibilidade para um agente de terapia para câncer, para estender um período de sensibilidade e para estender a duração da resposta para uma terapia para câncer, e usos | |
BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
BR112019007210A2 (pt) | métodos e composições para o tratamento da doença de fabry | |
DOP2012000265A (es) | Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores. | |
BR112015017241A2 (pt) | doadores de nitroxil com índice terapêutico melhorado | |
BR112018002530A2 (pt) | combinações e usos e tratamentos destas | |
BR112017018198A2 (pt) | inibição da atividade de olig2 | |
BR112018006810A2 (pt) | regimes de dosagem | |
BR112018003780A2 (pt) | composições que compreendem um composto de urolitina | |
MX2019001579A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
CO2019003865A2 (es) | Proteína terapéutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |